HARVARD BIOSCIENCE, INC. (NASDAQ:HBIO) Files An 8-K Changes in Registrant’s Certifying Accountant

HARVARD BIOSCIENCE, INC. (NASDAQ:HBIO) Files An 8-K Changes in Registrant’s Certifying Accountant

Story continues below

Item 4.01 Change in Registrants Certified Accountant.

The Audit Committee (the Audit Committee) of the Board of
Directors of Harvard Bioscience, Inc. (the Company) recently
solicited proposals from several accounting firms to serve as the
Companys registered independent accounting firm for the year
ending December 31, 2017 and 2018. As a result of this process
and after careful deliberation, on May 8, 2017, the Company
appointed Grant Thornton LLP (Grant Thornton) and dismissed KPMG
LLP (KPMG) as its independent registered public accounting firm,
effective immediately. These changes were approved by the
Companys Audit Committee.

During the two most recent fiscal years ended December 31, 2016
and 2015 and the subsequent interim period through May 8, 2017,
there were no disagreements (as that term is defined in Item
304(a)(1)(iv) of Regulation S-K) between KPMG and the Company on
any matter of accounting principles or practices, financial
statement disclosure or auditing scope or procedures, which
disagreements, if not resolved to KPMGs satisfaction, would have
caused KPMG to make reference in connection with its opinion to
the subject matter of the disagreement, nor were there any
reportable events (as that term is defined in Item 304(a)(1)(v)
of Regulation S-K), except that for the years ended December 31,
2016 and 2015, material weaknesses existed in the Companys
internal control over financial reporting, as identified and
described in managements assessment of the Companys internal
control over financial reporting as reported on its Form 10-K for
the fiscal years ended December 31, 2016 and 2015.

The audit reports of KPMG on the Companys consolidated financial
statements for the fiscal years ended December 31, 2016 and 2015
did not contain any adverse opinion or disclaimer of opinion, nor
were they qualified or modified as to uncertainty, audit scope or
accounting principles. The audit reports of KPMG on the
effectiveness of internal control over financial reporting as of
December 31, 2016 and 2015 did not contain any adverse opinion or
disclaimer of opinion, nor were they qualified or modified as to
uncertainty, audit scope or accounting principles, except that
KPMGs report for the fiscal year ended December 31, 2016 and 2015
indicated that the Company did not maintain effective internal
control over financial reporting as of December 31, 2016 and
2015. As described in the Companys Annual Report on Form 10-K for
the year ended December 31, 2016, management is committed to
remediating the material weaknesses in a timely fashion. The
Audit Committee has authorized KPMG to respond fully to the
inquiries of Grant Thornton concerning these material weaknesses.

The Company provided KPMG with a copy of the foregoing
disclosures prior to the filing of this Form 8-K and requested
KPMG furnish the Company with a letter addressed to the
Securities and Exchange Commission stating whether or not KPMG
agreed with the disclosure in this Item 4.01. A copy of this
letter is filed as Exhibit 16.1 to this Current Report on Form
8-K.

During the two most recent fiscal years ended December 31, 2016
and 2015 and the subsequent interim period through May 8, 2017
preceding the engagement of Grant Thornton as the Companys
independent registered public accounting firm, neither the
Company nor anyone acting on behalf of the Company consulted
Grant Thornton regarding either:

(i) The application of accounting principles to a specified
transaction, either completed or proposed, or the type of audit
opinion that might be rendered on the Companys consolidated
financial statements, and no written report or oral advice was
provided to the Company by Grant Thornton that Grant Thornton
concluded was an important factor considered by the Company in
reaching a decision as to any accounting, auditing, or financial
reporting issue; or

(ii) Any matter that was the subject of a disagreement (as
defined in Item 304(a)(1)(iv) of Regulation S-K) or a reportable
event (as defined in Item 304(a)(1)(v) of Regulation S-K).

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

Exhibit

Number

Title
16.1 Letter from KPMG to the Securities and Exchange Commission,
dated as of May 9, 2017.


About HARVARD BIOSCIENCE, INC. (NASDAQ:HBIO)

Harvard Bioscience, Inc. is a developer, manufacturer and marketer of a range of scientific instruments, systems and lab consumables used for basic research, drug discovery, clinical and environmental testing. The Company’s products are sold to thousands of researchers in over 100 countries through its global sales organization, Websites, catalogs and through distributors. The Company’s product range is organized into three commercial product families: Cell and Animal Physiology (CAP), Lab Products and Services (LPS), and Molecular Separation and Analysis (MSA). The Company sells these products under brand names, including Harvard Apparatus, KD Scientific, Denville Scientific, AHN, Hoefer, Biochrom, BTX, Warner Instruments, MCS, HEKA, Hugo Sachs Elektronik, Panlab, Coulbourn Instruments, TBSI and CMA Microdialysis. The Company’s products consist of instruments, consumables and systems that are made up of various individual products.

HARVARD BIOSCIENCE, INC. (NASDAQ:HBIO) Recent Trading Information

HARVARD BIOSCIENCE, INC. (NASDAQ:HBIO) closed its last trading session down -0.10 at 2.55 with 81,360 shares trading hands.

An ad to help with our costs